Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-03-27. The firm specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
根據最新的財務報表(Form-10K),Biocure Technology Inc. 的總資產為 $1,淨isProfitable}為 $0
BICTF 的關鍵財務比率是什麼?
Biocure Technology Inc. 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Biocure Technology Inc. 的收入按細分市場或地理位置如何劃分?
Biocure Technology Inc. 最大收入來源為 Telecommunications Services,在最近的收益報告中收入為 23,243,000,000。就地區而言,Hong Kong 是 Biocure Technology Inc. 的主要市場,收入為 28,154,000,000。